| Christopher James Britt, DO | |
|
203 Turnpike St, G1, North Andover, MA 01845-5042 | |
| (508) 209-1300 | |
| Not Available |
| Full Name | Christopher James Britt |
|---|---|
| Gender | Male |
| Speciality | Pain Medicine - Interventional Pain Medicine |
| Location | 203 Turnpike St, North Andover, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750779328 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | S38162650 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christopher James Britt, DO 15 Great Kame, Plymouth, MA 02360-6373 Ph: (774) 773-9726 | Christopher James Britt, DO 203 Turnpike St, G1, North Andover, MA 01845-5042 Ph: (508) 209-1300 |
News Archive
Limerick BioPharma, Inc., a developer of innovative therapies that help cells pump unwanted or toxic substances away from vulnerable tissues, has announced positive results of a Phase 1a trial for its lead compound, LIM-0705, which has completed its first in man study.
Astronauts who spend several months on the International Space Station have significant reductions in the size and density of paraspinal muscles of the trunk after returning to Earth, reports a study in Spine. The journal is published in the Lippincott portfolio by Wolters Kluwer.
More than one-third of counties in the Unites States are located more than 50 miles from the nearest gynecologic oncologist, making access to specialty care for ovarian and other gynecologic cancers difficult for nearly 15 million women. While most of these "low access" counties are located in the Mountain-West and Midwest regions, the findings of a recent study from researchers at the Perelman School of Medicine at the University of Pennsylvania also reveal that 47 states have at least one county located more than 50 miles from the nearest gynecologic oncologist.
A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.
Ventas, Inc. today announced that HCP, Inc. has agreed to pay it $125 million to settle the Company's outstanding lawsuit against HCP arising out of the Company's 2007 acquisition of Sunrise Senior Living REIT.
› Verified 6 days ago